Product Images Oxybutynin Chloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 5 images provide visual information about the product associated with Oxybutynin Chloride NDC 69189-6605 by Avera Mckennan Hospital, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Oxybutynin XL 5 mg tablet label - 6918966051
This is a description of a medication called Oxybutynin XL, manufactured by Mylan, in a 5mg tablet form. The medication comes with an expiration date of 11/10/2016 and a MFG Lot number of 3065924. Additionally, it has an NDC number of 6918966051. The hospital has also assigned their own lot number, which is APF15K11-F. There appears to be some random letters/numbers that cannot be interpreted as readable. The medication was likely received by the hospital AVEFUA McKENNAN in St Falls, SO.*
Figure 1: Mean R-Oxybutynin Plasma Concentrations Following a Single Dose of Oxybutynin Chloride Extended-release Tablets 10 mg and Oxybutynin 5 mg Administered Every 8 hours (n = 23 for Each Treatment). - Fig1
Mean plasma concentration of R-oxybutynin is being measured. There are references to oxybutynin 5 mg and ER 10 mg. No further context or details are available.*
Figure 2: Mean Steady State (± SD) R-Oxybutynin Plasma Concentrations following Administration of 5 to 20 mg Oxybutynin Chloride Extended-release Tablets Once Daily in Children Aged 5 to 15. Plot Represents All Available Data Normalized to an Equivalent of Oxybutynin Chloride Extended-release Tablets 5 mg Once Daily. - Fig2
Number of Urge Incontinence Episodes per Week - Fig3
This appears to be a description of the results from three studies comparing the effectiveness of oxybutynin chloride ER (extended release) to placebo or regular oxybutynin in treating an unknown condition. The studies measured changes from baseline and confidence intervals for the differences between the two groups. The results suggest that oxybutynin chloride ER had a statistically significant effect when compared to the placebo, and a comparable efficacy when compared to regular oxybutynin. There is not enough information to determine the specific condition being studied.*
Oxybutynin Chloride Structural Formula - Structure
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.